 |
Download our whitepaper to learn about the drawbacks of traditional pUC plasmid vectors, including antibiotic resistance marker transfer, potential risk of residual antibiotic-mediated hypersensitivities, horizontal gene transfer, and how Nanoplasmid’s next-generation design mitigates these shortcomings. In this whitepaper, you will learn about the current market trends and challenges within the cell and gene therapy (CGT) field, along with a guideline perspective of the Food and Drug Administration, European Medicines Administration, and World Health Organization relevant to clinical programs bound for commercialization. Additionally, you will learn how Nanoplasmid’s antibiotic-free system RNA-OUT system functions and how its R6K origin of replication will aid in the following:
|
